Lose Weight Faster With Semaglutide & Tirzepatide

Semaglutide Weight Loss in 2026: Evidence, Safety and the Rules

If you are considering semaglutide weight loss treatment, it helps to know how the medicine works, what each FDA label covers, what the major trials showed, and where compounded versions stand as of October 2026.

How GLP-1 medications work

GLP-1 is a hormone your body makes that helps regulate appetite and how much you eat. Semaglutide is a lab-made version with 94% sequence homology to human GLP-1. It activates the same receptor, which is found in several brain areas involved in appetite, according to the Wegovy prescribing information. The label says semaglutide lowers calorie intake, likely by affecting appetite. It also slows stomach emptying, which can change how other pills are absorbed.

Tirzepatide (Zepbound, Mounjaro) mimics GLP-1 and a second gut hormone, GIP. The NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) explains both in plain language.

FDA-approved options and what each label covers

Some products share an active ingredient but are approved for different conditions.

The weight-management labels call for a reduced-calorie diet and more physical activity alongside the medicine, and advise against combining it with another GLP-1 product. For a closer look at the two main ingredients, see our semaglutide vs. tirzepatide comparison.

Who the weight-management labels are written for

The pivotal semaglutide and tirzepatide obesity trials, and NIDDK guidance, use the same adult cutoffs:

• A body mass index (BMI) of 30 or higher, or
• A BMI of 27 or higher with at least one weight-related health problem, such as high blood pressure or type 2 diabetes.

A BMI number alone does not make semaglutide weight loss treatment right for you. A licensed provider also weighs your history, other medicines and the warnings below. See who qualifies for semaglutide for more detail.

What the pivotal trials showed

The strongest evidence for semaglutide weight loss comes from STEP 1. For tirzepatide, it is SURMOUNT-1.

Both trials studied FDA-approved injectable products alongside lifestyle counseling, and these are group averages, not promises. Semaglutide weight loss also depends on staying on treatment. In the STEP 1 extension, which followed 327 participants for a year after treatment stopped, people regained about two-thirds of their prior weight loss. NIDDK notes that if you have not lost at least 5% of your starting weight after 12 weeks on the full dose, your clinician will likely advise stopping the medicine and may suggest a different plan.

Side effects, the boxed warning and who should not use them

Digestive effects are the most common side effects of semaglutide weight loss treatment. The most common side effects on the Wegovy and Zepbound labels include nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, burping, reflux, fatigue and hair loss. Doses are raised gradually under a provider’s direction. For practical tips, see how to manage semaglutide side effects.

Boxed warning. Semaglutide and tirzepatide caused thyroid C-cell tumors in rodents. It is not known whether they cause these tumors, including medullary thyroid carcinoma (MTC), in people.

Do not use if you or a family member has had MTC, if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to the medicine.

Other serious label warnings:

• Pancreatitis (severe, lasting belly pain) and gallbladder disease
• Kidney injury from dehydration
• Severe digestive reactions; Wegovy is not recommended with severe gastroparesis
• Serious allergic reactions
• Low blood sugar when combined with insulin or sulfonylureas
• Worsening diabetic eye disease in people with type 2 diabetes
• Inhaling stomach contents during anesthesia or deep sedation

Pregnancy. These medicines may harm a developing baby. When they are used for weight reduction, the labels say to stop once pregnancy is recognized. The Wegovy label advises stopping at least two months before a planned pregnancy. The Zepbound label advises people on birth control pills to switch to a non-oral method, or add a barrier method, for four weeks after starting and after each dose increase.

Compounded semaglutide and tirzepatide: where things stand

According to the FDA, the shortage-era window for compounding has closed:

• Tirzepatide: FDA declared the shortage resolved on October 2, 2024, and reaffirmed that on December 19, 2024. Enforcement discretion for 503A pharmacies ended after a March 5, 2025 court ruling, and for 503B outsourcing facilities on March 19, 2025.
• Semaglutide: The shortage was declared resolved on February 21, 2025. The 503A period ended after an April 24, 2025 court ruling; the 503B period ended May 22, 2025.
• Copies are limited. A 503A pharmacy generally may not regularly make essentially a copy of an approved drug unless a prescriber documents a significant clinical difference for a specific patient.
• 503B bulk use. On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the list of bulk ingredients outsourcing facilities may use. It is a proposal, not a final decision.
• Marketing limits. On February 6, 2026, FDA said companies may not describe compounded products as generic, as the same as an approved drug, or as using the same active ingredient.

Compounded drugs are not FDA-approved, so FDA does not review them for safety, effectiveness or quality. FDA’s safety page warns about dosing errors, salt forms such as semaglutide sodium, counterfeit products, “research use only” products and unapproved drugs such as retatrutide. As of May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide. FDA also advises not using an injectable GLP-1 that arrives warm. If you compare semaglutide weight loss offers online, ask exactly what product you would get, and buy only from state-licensed pharmacies.

What monitoring looks like

Safe semaglutide weight loss care includes regular follow-up. Based on the labels, that usually covers:

• Weight, side effects and how you tolerate each dose increase
• Blood sugar before and during treatment if you have diabetes
• Kidney function if vomiting or diarrhea leads to dehydration
• Heart rate, and eye checks if you have diabetic eye disease
• Warning signs of pancreatitis or gallbladder problems
• Upcoming surgery or sedation, and any pregnancy plans

Because these medicines can change how other pills are absorbed, keep your medication list current.

How online semaglutide weight loss care works at MultiGen

1. Consult. You meet a licensed provider by telehealth to review your goals, history, medicines and risk factors.
2. Labs if needed. Your provider may ask for recent results or order new tests.
3. The provider decides. If a GLP-1 medicine is appropriate, the provider prescribes only what is suitable and legally available. You can always ask whether a medicine is an FDA-approved product or a compounded one. If it is not a fit, you will hear that too.
4. Follow-up. Regular visits track progress, side effects and the monitoring items above.

MultiGen is a self-pay practice: $247 to start, which includes your first provider visit, then $97 per visit. Medications are priced separately; see live prices on our pharmacy page. MultiGen does not bill insurance and does not take HSA or FSA cards directly.

Semaglutide weight loss FAQs

Is Ozempic the same as Wegovy?

Both contain semaglutide, but the labels differ. Wegovy is approved for weight management; Ozempic is approved for type 2 diabetes.

How much weight can I expect to lose?

Average semaglutide weight loss in STEP 1 was 14.9% over 68 weeks. In SURMOUNT-1, tirzepatide averaged up to 20.9% over 72 weeks at the highest dose. Those results come from FDA-approved products, and yours may be higher or lower.

What happens if I stop?

Weight often comes back. In the STEP 1 extension, people regained about two-thirds of their prior weight loss within a year of stopping.

Is compounded semaglutide FDA-approved?

No. Compounded drugs are not FDA-approved, and now that the shortages have ended, federal law sharply limits when pharmacies may compound copies of approved GLP-1 drugs.

Do I need lab work first?

Sometimes. Before semaglutide weight loss treatment starts, your provider decides based on your history.

Does MultiGen take insurance or HSA/FSA cards?

No. MultiGen is self-pay, does not bill insurance and does not take HSA or FSA cards directly.

Talk to a licensed provider

Want to know whether a GLP-1 medicine is safe and right for you? Contact MultiGen Wellness or call 1-800-259-0015 to schedule a visit with a licensed provider.